R&D

글로벌 바이오 헬스큐어 기업 제넨셀

논문

The CH2Cl2 Extract Fraction from Ficus erecta var. sieboldii (Miq.) King Suppresses Lipopolysaccharide-mediated Inflammatory Responses in Raw264.7 Cells

첨부파일

본문

(주)제넨셀은 염증 억제에 도움을 줄 수 있는 건강기능식품 및 의약품의 개발을 위해

다양한 소재에 대한 연구를 지속적으로 하고 있으며, 이들을 통한 사업화를 추진하고 있습니다.


해당 논문은 경희대학교와 공동연구를 통해 대식세포 (macrophage)에서

F. erecta extracts, the CH2Cl2 fraction (CFE)의 항염증 효능을 입증하였습니다. 

이를 통해 CFE의 항염증제로서의 가능성을 제시하였으며,

국제저명학술지 Journal of Food and Nutrition Research (IF 0.927) 에 게재되었습니다.

해당 논문은 추후 CFE의 전임상 및 임상시험, 사업화의 기초자료로 활용될 예정입니다.


Abstract

A phytochemical application of leaves from Ficus erecta var. sieboldii (Miq.) King has not been widely investigated. We determined an anti-inflammatory effect of F. erecta extracts on lipopolysaccharide  (LPS)-mediated production through modulation of several pro-inflammatory mediators and prostaglandin E2 (PGE2). Among the F. erecta extracts, the CH2Cl2 fraction (CFE) most effectively suppressed the LPS-mediated production of nitric oxide (NO) in Raw264.7 cells. As determined by immunoblotting and PCR, CFE was shown to have an inhibitory effect on LPS-induced mRNA and protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). In addition, CFE showed significant inhibitory effects on LPS-mediated production of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and PGE2 (P<0.05), demonstrating its effects on inflammation. The main active compounds that suppressed PGE2 production were syringaresinol (C1) and 6,7-furano-5-methoxy hydrocoumaric acid (C2). In conclusion, CFE showed an inhibitory effect on LPS-mediated inflammatory responses by suppressing iNOS, COX-2, TNF-α, IL-1β, and IL-6 production. The compounds C1 and C2 showed strong inhibitory effects on LPS-mediated production of PGE2 and may be applicable as starter compounds for developing anti-inflammatory and anti-nociceptive drugs. 

 

Keywords Ficus erecta var. sieboldii (Miq.) King, Inflammation, Cyclooxygenase-2, Prostaglandin E2, Proinflammatory cytokine, Syringaresinol, 6,7-Furano-5-methoxy Hydrocoumaric acid